CARMAT |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.15 EUR | -2.63% |
|
-17.21% | -52.99% |
| Mar. 25 | Carmat: final agreement with creditors | CF |
| Mar. 25 | Carmat Secures Two-year Extensions for Bank Loans | MT |
| Sales 2023 | 2.8M 2.99M | Sales 2024 * | 23.05M 24.65M | Capitalization | 78.06M 83.47M |
|---|---|---|---|---|---|
| Net income 2023 | -53M -56.67M | Net income 2024 * | -38M -40.63M | EV / Sales 2023 | 59.2 x |
| Net Debt 2023 * | 49.63M 53.07M | Net Debt 2024 * | 68.9M 73.67M | EV / Sales 2024 * | 6.38 x |
| P/E ratio 2023 * |
-1.52
x | P/E ratio 2024 * |
-2.66
x | Employees | 177 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 85.45% |
More Fundamentals
* Assessed data
More news
Latest transcript on CARMAT
More press releases
More news
| 1 day | -2.63% | ||
| 1 week | -17.21% | ||
| Current month | -23.45% | ||
| 1 month | -20.65% | ||
| 3 months | -29.21% | ||
| 6 months | +3.28% | ||
| Current year | -52.99% |
1 week
3.08
3.92
1 month
3.084.20
Current year
3.087.72
1 year
3.009.99
3 years
3.0031.70
5 years
3.0036.00
10 years
3.0096.00
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Piat
CEO | Chief Executive Officer | - | 16-08-31 |
Alain Carpentier
FOU | Founder | 91 | 08-06-24 |
| Director of Finance/CFO | - | 18-12-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alexandre Conroy
CHM | Chairman | 61 | 22-12-21 |
| Director/Board Member | 85 | 16-04-11 | |
Pierre Bastid
BRD | Director/Board Member | 69 | 18-04-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 3.15 | -2.63% | 63,346 |
| 24-04-25 | 3.235 | -6.50% | 146,450 |
| 24-04-24 | 3.46 | -8.47% | 88,066 |
| 24-04-23 | 3.78 | 0.00% | 25,402 |
| 24-04-22 | 3.78 | -0.66% | 20,171 |
Real-time Euronext Paris, April 26, 2024 at 11:35 am EDT
More quotes
CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.15
EUR
Average target price
14.22
EUR
Spread / Average Target
+351.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -52.99% | 83.34M | |
| +12.07% | 128B | |
| -9.04% | 10.65B | |
| +0.91% | 8.82B | |
| +16.72% | 7.19B | |
| +25.15% | 4.99B | |
| +7.17% | 3.4B | |
| -1.36% | 3.03B | |
| -8.73% | 2.14B | |
| -10.15% | 2B |
- Stock Market
- Equities
- ALCAR Stock
